Passage Bio, Inc.

Healthcare · Biotechnology · United States

Last price 3.45 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 11.10M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding β-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington’s...